title: Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus.
abstract: Cyclosporine (CsA) and tacrolimus (FK506) have recently been reported to inhibit canalicular transport of bile acids in vitro and thereby possibly induce cholestasis. A relative reduction of chenodeoxycholic acid (CDCA) has been observed after liver transplantation when CsA is used as immunosuppressant. We tested the hypothesis that CsA induces cholestasis and reduces CDCA secretion as compared with treatment with monoclonal antibodies (OKT3), and that CsA differs from FK506 with regard to its effects on biliary lipid secretion. Bile flow, biliary lipid secretion rates, and biliary bile acid composition were determined during the first 10 days after transplantation in 29 liver transplant recipients. Two prospective randomized studies were performed that compared CsA and OKT3 and compared CsA- and FK506-based regimens. In study 1, bile acid output averaged 0.75+/-0.15 micromol/min in the CsA I group and 0.54+/-0.11 micromol/min in the OKT3 group on postoperative day 1. Bile flow and bile acid output then increased, and there was no significant difference between the two groups. The relative proportion of CDCA decreased to the same extent in both groups. In study 2, mean bile acid outputs on postoperative day 1 were 0.57+/-0.26 micromol/min and 0.55+/-0.15 micromol/min in the CsA 2 and FK506 groups, respectively. The following increase in bile acid secretion was significantly larger in the FK506 group. After transplantation, the relative proportion of CDCA decreased with time in both groups, but the reduction was more rapid in the FK506 group. In conclusion, CsA did not inhibit bile secretion during short-term treatment after liver transplantation. Compared with patients given CsA-based treatment, patients with FK506-based treatment recovered bile secretion more rapidly.
authors.affiliation: Department of Transplantation Surgery, Huddinge University Hospital, Sweden.
authors.forename: B G
authors.initials: BG
authors.lastname: Ericzon
authors.forename: S
authors.initials: S
authors.lastname: Eusufzai
authors.forename: G
authors.initials: G
authors.lastname: Söderdahl
authors.forename: F
authors.initials: F
authors.lastname: Duraj
authors.forename: K
authors.initials: K
authors.lastname: Einarsson
authors.forename: B
authors.initials: B
authors.lastname: Angelin
mesh_terms: D000328:Adult; D001646:Bile / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D002635:Chenodeoxycholic Acid / Q000032:analysis; D019826:Cholic Acid; D002793:Cholic Acids / Q000032:analysis; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects; D011446:Prospective Studies; D016559:Tacrolimus / Q000009:adverse effects*
chemical_list: D002793:Cholic Acids; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D002635:Chenodeoxycholic Acid; D016572:Cyclosporine; D019826:Cholic Acid; D016559:Tacrolimus